Literature DB >> 2379037

Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina.

M J Neal1, M A Shah.   

Abstract

1. The effects of acute and chronic vigabatrin (gamma-vinyl-GABA) (GVG) administration on gamma-aminobutyric acid (GABA) levels and release in rat cortical slices, spinal cord slices and retinas were studied. 2. GVG (250 mgkg-1 i.p.) administered to rats 18 h before death (acute administration) produced an almost 3 fold increase in GABA levels of the cortex and spinal cord and a 6 fold increase in retinal GABA. The levels of glutamate, aspartate, glycine and taurine were unaffected. 3. When GVG (250 mgkg-1 i.p.) was administered daily for 17 days (chronic administration) a similar (almost 3 fold) increase in cortical GABA occurred but the increases in spinal and retinal GABA were reduced by approximately 40%. 4. Acute administration of GVG strikingly increased the potassium-evoked release (KCl 50 mM) of GABA from all three tissues. This enhanced evoked release was reduced by about 50% in tissues taken from rats that had been chronically treated with GVG. 5. Acute administration of GVG reduced GABA-transaminase (GABA-T) activity by approximately 80% in cortex and cord and by 98% in the retina. Following the chronic administration of GVG, there was a trend for GABA-T activities to recover (significant only in cortex). Acute administration of GVG had no effect on glutamic acid decarboxylase (GAD) activity in cortex or spinal cord. However, chronic treatment resulted in significant decreases in GAD activity in both the cortex and cord (35% and 50% reduction respectively). 6. The K-evoked release of glutamate, aspartate, glycine and taurine from cortical slices and the Kevoked release of glycine from spinal slices and retinas were not affected by either acute or chronic GVG treatment. 7. These experiments indicate that GVG treatment increases specifically the K-evoked release of GABA and that tolerance can develop to this enhancing effect of GVG on central GABA release. This tolerance may result from increased feedback inhibition of GAD with a consequent reduction of presynaptic GABA stores.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379037      PMCID: PMC1917440          DOI: 10.1111/j.1476-5381.1990.tb15803.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  The distribution of glutamic-gamma-aminobutric transaminase in the nervous system of the rhesus monkey.

Authors:  R A SALVADOR; R W ALBERS
Journal:  J Biol Chem       Date:  1959-04       Impact factor: 5.157

2.  Subcellular distribution of endogenous and (3H) gamma-aminobutyric acid in rat cerebral cortex.

Authors:  M J Neal; L L Iversen
Journal:  J Neurochem       Date:  1969-08       Impact factor: 5.372

3.  4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain.

Authors:  B Lippert; B W Metcalf; M J Jung; P Casara
Journal:  Eur J Biochem       Date:  1977-04-15

4.  Effects of anticonvulsants on the in vivo and in vitro release of GABA.

Authors:  A S Abdul-Ghani; J Coutinho-Netto; D Druce; H F Bradford
Journal:  Biochem Pharmacol       Date:  1981-02-15       Impact factor: 5.858

5.  gamma-Aminobutyric acid metabolism in rat brain following chronic oral administration of ethanolamine O-sulphate.

Authors:  A Fletcher; L J Fowler
Journal:  Biochem Pharmacol       Date:  1980-06-01       Impact factor: 5.858

6.  Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, gamma-acetylenic GABA (4-amino-hex-5-ynoic acid) and gamma-vinyl GABA (4-amino-hex-5-enoic acid).

Authors:  B Meldrum; R Horton
Journal:  Psychopharmacology (Berl)       Date:  1978-09-15       Impact factor: 4.530

7.  On the mechanism by which veratridine causes a calcium-independent release of gamma-aminobutyric acid from brain slices.

Authors:  J Cunningham; M J Neal
Journal:  Br J Pharmacol       Date:  1981-07       Impact factor: 8.739

8.  The action of gamma-vinyl-GABA and gamma-acetylenic-GABA on the resting and stimulated release of GABA in vivo.

Authors:  A S Abdul-Ghani; J Coutinho-Netto; H F Bradford
Journal:  Brain Res       Date:  1980-06-09       Impact factor: 3.252

9.  Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid).

Authors:  J Grove; P J Schechter; G Tell; J Koch-Weser; A Sjoerdsma; J M Warter; C Marescaux; L Rumbach
Journal:  Life Sci       Date:  1981-05-21       Impact factor: 5.037

10.  Anticonvulsant and biochemical effects of inhibitors of GABA aminotransferase and valproic acid during subchronic treatment in mice.

Authors:  W Löscher
Journal:  Biochem Pharmacol       Date:  1982-03-01       Impact factor: 5.858

View more
  17 in total

1.  Effects of gamma-vinyl GABA (vigabatrin) on blood pressure and body weight of hypertensive and normotensive rats.

Authors:  N Singewald; A Pfitscher; A Philippu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

Review 2.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

3.  Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow.

Authors:  S L Hosking; E J Roff Hilton; S J Embleton; A K Gupta
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

4.  The rate of turnover of cortical GABA from [1-13C]glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA).

Authors:  D Manor; D L Rothman; G F Mason; F Hyder; O A Petroff; K L Behar
Journal:  Neurochem Res       Date:  1996-09       Impact factor: 3.996

5.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

Review 6.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

7.  The effects of GABA and vigabatrin on horizontal cell responses to light and the effect of vigabatrin on the electroretinogram.

Authors:  R Hanitzsch; L Küppers
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

8.  Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.

Authors:  W Löscher; D Hörstermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

9.  Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.

Authors:  M Holbrook; S J Coker
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

10.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

Authors:  J Raymond Buncic; Carol A Westall; Carole M Panton; J Robert Munn; Leslie D MacKeen; William J Logan
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.